Antisense Pharma GmbH, a Regensburg, Germany-based biopharmaceutical company which develops and markets novel drugs for the targeted treatment of particularly aggressive cancers, raised €13m in equity financing.
Participants in the round include existing investors MIG Fonds (€11m), the Global Asset Fund (€1.5m), other private investors and the management of the company.
With the new investments, just under €80m of venture capital has been raised.
The funds will be used for the further clinical development of Antisense Pharma’s flagship product, trabedersen, which is currently in Phase III of the clinical study for the indication of malignant brain tumours (WHO Grade III).
Also, a Phase II/III Study into advanced pancreatic cancer is being prepared at the moment.